Relmada Therapeutics (NASDAQ:RLMD) Announces Earnings Results

Relmada Therapeutics (NASDAQ:RLMD) issued its quarterly earnings results on Monday. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.27), Zacks reports.

Relmada Therapeutics Stock Down 5.1%

RLMD traded down $0.02 during trading on Monday, reaching $0.40. 774,375 shares of the stock traded hands, compared to its average volume of 895,730. The stock has a market capitalization of $13.22 million, a PE ratio of -0.14 and a beta of 0.18. The stock’s 50-day moving average is $0.33 and its 200 day moving average is $0.90. Relmada Therapeutics has a 12 month low of $0.24 and a 12 month high of $4.47.

Relmada Therapeutics Company Profile

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.